A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy

Clinical trial NCT07752264 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07752264
Sponsor: Nanjing IASO Biotechnology Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory Immune-mediated Necrotizing Myopathy

Start date: 2026-08-15
Primary completion: 2030-08-15
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.